IPN Ipsen SA

Ipsen : Déclaration des transactions sur actions propres réalisées du 15 au 19 Août 2022

Regulatory News:

Présentation agrégée par jour et par marché

Nom de l'émetteur

Code identifiant de l'émetteur

(code LEI)

Jour de la

transaction

Code identifiant de

l'instrument financier

Volume total journalier

(en nombre de titres)

Prix pondéré

moyen journalier

d'acquisition

Code

identifiant

marché

IPSEN

549300M6SGDPB4Z94P11

16/08/2022

FR0010259150

1 697

96,9538

XPAR

IPSEN

549300M6SGDPB4Z94P11

17/08/2022

FR0010259150

2 000

96,8226

XPAR

IPSEN

549300M6SGDPB4Z94P11

18/08/2022

FR0010259150

1 100

96,1234

XPAR

 

 

 

TOTAL

4 797

96,7087

 

FR
23/08/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ipsen SA

Christophe-Raphaël Ganet
  • Christophe-Raphaël Ganet
Christophe-Raphaël Ganet
  • Christophe-Raphaël Ganet
 PRESS RELEASE

Ipsen delivers strong results in 2025, driven by solid execution acros...

Ipsen delivers strong results in 2025, driven by solid execution across all therapeutic areas, and provides 2026 guidance FY 2025 sales growth of 10.9% at CER1, or 8.1% as reported, driven by growth of the three therapeutic areas of Oncology (4.1%1), Rare Disease (102.5%1) and Neuroscience (9.7%1); Somatuline® sales growth of 4.3%1, with all other products, excluding Somatuline, achieving double-digit sales growth of 14.2%1FY 2025 core operating income of €1,294m, growing by 16.7% as reported, with a core operating margin of 35.2% of total sales, increasing by 2.6 points2025 continued pipel...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch